Manage Your Career with Confidence and Strategic Planning

2014 SAPA-GP Career Development Workshop Co-Chairs: Fang Shen Tianjing (TJ) Hu Zhenghua Wu Organizing Committee: Xi-Yong Sean Fu Aston Liu Weiguo Dai Yin Liang Jing Yang Bin Shi Mabel Ju Huaping Tang Hui Wang Hao Wu Steve Wu Lili Guo Yangsi Ou Bei Chen Kun Wang Kelvin Bai Aming Zhang Art Design: Steve Wu Follow us on Weibo Visit our website http://weibo.com/sapagp http://sapa-gp.org

Agenda

8:30 AM – 9:00 AM Registration and Check-in

9:00 AM – 9:15 AM Welcome Remarks Xi-Yong (Sean) Fu, PhD, MBA

President, SAPA-GP; Director, Financial Services and Operations, Merck & Co., Inc.

9:15 AM – 10:00 AM Career Development: Follow Your Passion with a Balance of Self-improvement and Opportunities

Ming Wang, PhD Vice President and Diabetes Disease Area Leader, Janssen Pharmaceuticals/Johnson & Johnson

10:00 AM – 10:55 AM KEYNOTE: Leading the Life You Want: Skills for Integrating Work and Life

Stewart D. Friedman, PhD

Practice Professor of Management, Director, Wharton Work/Life Integration Project

11:55 AM – 11:05 AM Coffee Break

11:05 AM – 12:00 PM Breakout Session A

How to handle “glass ceiling” & “culture hurdle”? How to manage life's priorities for career professionals? Panelists: Ming Wang, PhD

Stewart D. Friedman Gui-Bai Liang, PhD

Moderators: TBD

12:00 PM – 1:00 PM Lunch & Social Hour Book signing by Stewart D. Friedman, PhD “Leading the Life You Want: Skills for Integrating Work and Life”

1:00 PM – 1:45 PM Diversity & Inclusion in the Workplace: An Asian-American Perspective

Chris Takimoto, MD, PhD

Vice President, Experimental Medicine Early Development, Oncology Therapeutic Area, Janssen R&D

1:45 PM – 2:30 PM Title: Career Development in Headhunter’s Eyes Peter Liu

Managing Consultant, Cornerstone Global Partners

2:30 PM – 2:40 PM Coffee Break

2:40 PM – 3:25 PM Title: Create Value beyond Labs - a Personal Account of Career That Embraces Both Science and Business

Bing Yuan, PhD Executive Director, Business Development and Licensing – Oncology, Merck & Co., Inc.

3:25 PM – 4:25 PM Breakout Session B

How does career planning work for me? How to build long term action plan to chart future career? How to improve communication to foster teamwork? Panelists: Chris Takimoto, MD, PhD Bing Yuan, PhD

Peter Liu Moderators: TBD

4:25 PM – 4:40 PM Closing Remarks & Raffle Drawing

Aston Liu, PhD

President Elect, SAPA-GP; Senior Manager, GlaxoSmithKline

Meet Speakers & Panelists Listed in Alphabetical Order

Stewart D. Friedman, PhD

Practice Professor of Management, Director, Wharton Work/Life Integration Project Since 1984 Stew Friedman has been at Wharton, where he is the Practice Professor of Management. In 1991 he founded both the Wharton Leadership Program – initiating the required MBA and Undergraduate leadership courses – and the

Wharton Work/Life Integration Project. Stew served for five years in the mental health field before earning his PhD in organizational psychology from the University of Michigan. In 2001, he concluded a two-year assignment (while on leave from Wharton) at Ford, as the senior executive for leadership development. In partnership with the CEO, he launched a portfolio of initiatives to transform Ford’s culture; 2500+ managers per year participated. Following these efforts, a research group (ICEDR) hailed Ford as a “global benchmark” in leadership development. Stew’s most recent book is Baby Bust: New Choices for Men and Women in Work and Family (Wharton Digital Press, 2013). He is author of the award-winning bestseller, Total Leadership: Be a Better Leader, Have a Richer Life (Harvard Business, 2008). It describes his challenging Wharton course (originally produced at Ford), in which participants do real- world exercises to increase their leadership performance in all parts of their lives by better integrating them, while working in peer-to-peer coaching relationships and using an innovative social learning site. The Total Leadership program – which marries the work/life and leadership development fields – is now used by individuals and organizations worldwide, including the 57K+ students in his recent Coursera course. The Total Leadership Web site was chosen as one of Forbes’ best for women. Forthcoming in October 2014 is his next book, Leading the Life You Want: Skills for Integrating Work and Life (Harvard Business). Stew’s other publications include the widely-cited Harvard Business Review articles, “Work and life: the end of the zero-sum game” (1998) and “Be a better leader, have a

richer life” (2008), and “The Happy Workaholic: a role model for employees” (Academy of Management Executive, 2003). His Work and Family – Allies or Enemies? (Oxford, 2000) was recognized by the Wall Street Journal as one of the field’s best books. In Integrating Work and Life: The Wharton Resource Guide (Jossey-Bass, 1998), Stew edited the first collection of learning tools for building skills for integrating work and life. He has advised many organizations, including the U.S. Departments of Labor and State, the U.N., and two White House administrations. He gives high-energy keynotes, conducts interactive workshops, and is an award-winning teacher. The New York Times cited the “rock star adoration” he inspires in students. He was chosen by Working Mother as one of America’s 25 most influential men to have made things better for working parents, and by Thinkers50 as one of the “world’s top 50 business thinkers.” The Families and Work Institute honored him with a Work Life Legacy Award in 2013. Follow on Twitter @StewFriedman. Tune in to his show, Work and Life, on Sirius XM 111, Business Radio Powered by the Wharton School, Tuesdays at 7:00 PM EDT.

Gui-Bai Liang, PhD Executive director of medicinal chemistry, and site operation leader of US-based China Business units, WuXi AppTec. Gui-Bai earned his Ph.D. in chemistry from University of Wisconsin-Madision. After postdoctoral training at Cornell University, he joined Merck Research Laboratories, and started his career as a senior medicinal chemist. His experience of drug

discovery at Merck has covered a wide range from early stage target validation and lead discovery, to late stage lead optimization and preclinical candidate nomination. He worked as a senior member of the hugely successful DPP-4 inhibitor program, which discovered the blockbuster drug Januvia. Later at Merck, Gui-Bai was a collaboration lead in External Basic Research, in charge of CRO collaborations. He worked extensively with CRO’s in China and India. After joining WuXi in 2012, Gui-Bai has worked in several areas of business development, overseeing integrated collaboration, and now in site operation. In recent years, Dr. Liang started publishing in various Chinese newspapers and magazines, including a recent popular book “Stories of Drug Discovery”.

Peter Liu

Managing Consultant, Cornerstone Global Partners Peter brings 5+ years of executive search and talent consulting experience to his clients. Currently he leads the pharmaceutical R&D in Life Science at Cornerstone Global Partners serving both multinational and fast growing domestic companies. Prior to Cornerstone Global Partners Peter was with a leading international recruitment solutions firm. He set up pharmaceutical team to handle Director and above levels positions and was responsible for developing long-term partnerships. He successfully manages the relationship with

clients and candidates; make surveys of source companies and collect information of the talent market to bring value to clients. Prior to starting his recruiting career Peter has more than 10 years of experiences in the Operation Management covering pharmaceutical, medical devices, FMCG and IT industry. With his last position as the senior manager, he was responsible for the company’s pharmaceutical and medical device procurement, import and export, vendor management, supply strategy operation and cost control. Peter holds a Master degree of Business Management and a Bachelor of International Trade and English from University of international business and economics.

Chris Takimoto, MD, PhD

Vice President, Experimental Medicine Early Development, Oncology Therapeutic Area, Janssen R&D Chris H. Takimoto, MD, PhD grew up in southern California and graduated from Stanford University in 1979 with a B.S. degree in Chemistry. He received a Ph.D. in Pharmacology and an M.D. degree from Yale University in 1986. After finishing residency training in Internal Medicine at the University of California, San Francisco in 1989, he moved to Bethesda, Maryland to complete a fellowship in Medical Oncology at the National Cancer Institute in 1993 and a second fellowship in

Clinical Pharmacology at the Uniformed Services University of the Health Sciences in 1996. From 1996 to 2000, he served as a Senior Investigator in the Developmental Therapeutics Department in the Medicine Branch at the National Cancer Institute and as an Assistant Professor of Medicine in the Division of Clinical Pharmacology at the Uniformed Services University. In 2000, he moved to the University of Texas Health Science Center at San Antonio (UTHSCSA) as an Associate Professor of Medicine in the Division of Medical Oncology. From 2004 to 2007, he held the position of Director of Pharmacology at the Institute for Drug Development (IDD) at the Cancer Therapy & Research Center (CTRC) in San Antonio, TX, where he was also the Zachry Chair for Translational Research. Dr. Takimoto was also an Adjunct Professor of Pharmacology at the UTHSCSA. In 2007, he became one of the founding members of the South Texas Accelerated Research Therapeutics (START) in San Antonio, an independent clinical research center dedicated to early phase oncology trials. In 2008, Dr. Takimoto moved to Johnson & Johnson, where he is currently Vice President and head of Experimental Medicine Early Development in the Oncology Therapeutic Area at Janssen R&D, LLC, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Takimoto's research interests include the pharmacology of new anticancer agents, oncology drug development, pharmacokinetics and pharmacodynamics, Phase I clinical trials, and novel treatments for gastrointestinal malignancies. He has published over 160 research articles, reviews, editorials, and book chapters. He has served on the editorial board of the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Investigational New Drugs, and several other oncology publications.

Ming Wang, PhD

Vice President and Diabetes Disease Area Leader Janssen Pharmaceuticals/Johnson & Johnson Dr. Ming Wang is currently Vice President and Disease Area Leader of Diabetes at Janssen Pharmaceuticals of J&J. In this role, he is responsible for setting strategies for disease area portfolio and leading the R&D team that is accountable for the development and execution of a business plan for drug

discovery and development in the diabetes arena. Previously, he was President and Chief Operating Officer of Gan & Lee Pharmaceuticals, a biotech pioneer in China focused on insulin-based therapies with annual sales of ~$100 million. He was also a member of the Board of Directors in the company. Prior to that, Ming was Executive Director and Head

of Diabetes Research at Amgen where he headed a group of ~50 scientists located on two research sites working on developing novel therapies for metabolic diseases. Before joining Amgen, Ming championed drug discovery programs and managed corporate partnerships in Parke-Davis, Pfizer and Pharmacia. Ming played important roles in building Amgen’s diabetes portfolio, supporting clinical development programs and facilitating licensing efforts. He served on the general medicine commercialization committee and helped set portfolio strategies. During his tenure at Amgen, he managed two corporate partnerships valued at more than $60 million and $86 million, respectively. Ming served on multiple advisory boards, including the Scientific Advisory Board (SAB) of Amgen Ventures ($100 million in management). Ming is a frequent speaker at scientific and drug discovery conferences and has 59 publications and a book entitled “Metabolic Syndrome: underlying mechanisms and drug therapies” (publisher: John Wiley & Sons, Inc.). Ming is also an adjunct faculty in the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco Schools of Pharmacy and Medicine.

Bing Yuan, PhD Executive Director, Business Development and Licensing – Oncology, Merck & Co., Inc. In his current role, Bing is responsible for search and evaluation of clinical stage oncology assets. Before joining Merck, Bing spent 6.5 years at Novartis Oncology and held various global strategic marketing roles with increasing responsibilities, including early and late stage new product planning (e.g.

driving lung cancer disease area strategy), business development evaluation (e.g. licensing Jakavi from Incyte) and Executive Director, Head of Life Cycle Strategy for established oncology brands (e.g. Glivec /Gleevec, Afinitor loss of exclusivity planning). Bing also played a key role in designing initial Zykadia clinical development plan /fast-to-market strategy, and participated in recent global launch of Zykadia in ALK+ lung cancer. Before Novartis, Dr. Yuan was global strategic marketing lead for Eisai’s oncology portfolio. He championed creation of Halaven global launch plan and led commercial strategy development for 3 years. Bing started his career as a Senior Analysis at Acumen Sciences and a Product Manager at Fisher Scientific. Bing holds a BS in Biochemistry from Nanjing University, a Ph.D. in Molecular Biology from Columbia University and an MBA from Cornell University.

Established in December 2000, WuXi AppTec (NYSE: WX)

is a leading global pharmaceutical, biopharmaceutical, and

medical device open-access capability and technology

platform with operations in China and the United States.

As an innovation-driven and customer-focused company,

WuXi AppTec provides a broad and integrated portfolio of

services throughout the drug R&D process.

Our services are designed to help our worldwide customers

shorten the discovery and development time and lower the

cost of drug and medical device R&D through cost-effective

and efficient outsourcing solutions.

Contact Us

Mail: Xing_shaoguo@wuxiapptec.com

Tel：0086-021-50462808 /Mobile: +011+86+ 13910855041

Address: Shanghai, China

http://www.wuxiapptec.com.cn/global recruitment.html

CGP is a China centric recruitment

solutions firm with a global reach

through offices in Greater China

and 60 network offices around the

globe. CGP provides

multi-national clients entering or

expanding operations in China and

Chinese companies going

outbound with a range of talent

acquisition and talent

management solutions. These

services include traditional C-level

to mid-level executive search,

market entry/ outbound

investment consultancy and

organizational design solutions

through their industry specialized

Partners and Consultants.

www.cornerstoneglobalpartners.comC-level to mid-level Search Services

Assessment Process Service

Salary Negotiation Service

CGP Executive Search

Talent Competitors Organization

Compensation Strategies

Reference Check

CGP Talent Mapping

Talent Management Consulting

Talent Acquisition

Organizational Design

Reference Check Service

908B/F Tower A, Beijing Fortune Plaza, 7 Dongsanhuan Zhong Road, Chaoyang

District, Beijing, 100020, PRC

Tel：+86 10 6530 9192

Inbound/Outbound Advisory

Localized Business Strategies

Due Diligence for M&A activity

Chinese CompanyOverseas Expansion